Daily Stock Analysis, ACRX, AcelRx Pharmaceuticals Inc, priceseries

AcelRx Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.05
Close
3.08
High
3.15
Low
3.00
Previous Close
3.00
Daily Price Gain
0.08
YTD High
3.60
YTD High Date
Mar 3, 2017
YTD Low
2.45
YTD Low Date
Jan 9, 2017
YTD Price Change
0.53
YTD Gain
20.59%
52 Week High
4.08
52 Week High Date
Sep 28, 2016
52 Week Low
2.40
52 Week Low Date
Jun 28, 2016
52 Week Price Change
-0.02
52 Week Gain
-0.81%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 18. 2014
6.39
Jan 6. 2015
6.71
11 Trading Days
5.04%
Link
LONG
Feb 11. 2015
7.24
Mar 6. 2015
8.58
16 Trading Days
18.45%
Link
LONG
Apr 10. 2015
4.06
Apr 27. 2015
4.35
11 Trading Days
7.20%
Link
LONG
May 29. 2015
3.50
Jun 17. 2015
4.04
13 Trading Days
15.42%
Link
LONG
Oct 30. 2015
3.94
Dec 1. 2015
5.25
21 Trading Days
33.35%
Link
LONG
Jan 25. 2016
3.13
Feb 8. 2016
3.36
10 Trading Days
7.20%
Link
LONG
Jul 5. 2016
2.77
Jul 19. 2016
2.96
10 Trading Days
6.90%
Link
LONG
Jul 26. 2016
3.00
Aug 16. 2016
3.58
15 Trading Days
19.34%
Link
LONG
Sep 14. 2016
3.28
Oct 6. 2016
3.76
16 Trading Days
14.78%
Link
Company Information
Stock Symbol
ACRX
Exchange
NasdaqGM
Company URL
http://www.acelrx.com
Company Phone
650-216-3500
CEO
Howard B. Rosen
Headquarters
California
Business Address
351 GALVESTON DRIVE, REDWOOD CITY, CA 94063
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0001427925
About

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain in the United States.

Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain in the United States. The company's lead product candidates include ARX-04, a sufentanil sublingual tablet that is in Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings; and Zalviso, a sufentanil sublingual tablet system, which is in Phase III clinical trials for the treatment of moderate-to-severe acute pain in hospitalized adult patients. It is also developing ARX-03, a fixed-dose sufentanil/triazolam sublingual tablet, which has been completed Phase II clinical trial for mild sedation and pain relief during painful procedures. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.